**STROBE Statement—checklist of items that should be included in reports of observational studies**

|  |  |  |  |
| --- | --- | --- | --- |
|  | Item No | Recommendation | Page  No |
| **Title and abstract** | 1 | (*a*) Indicate the study’s design with a commonly used term in the title or the abstract | Abstract |
| (*b*) Provide in the abstract an informative and balanced summary of what was done and what was found | Abstract |
| Introduction | | | |
| Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported | Introduction page 3 |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses | Introduction page 3 |
| Methods | | | |
| Study design | 4 | Present key elements of study design early in the paper | Abstract and Methods pages 4-7 |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | Abstract and Methods page 4 |
| Participants | 6 | (*a*) *Cohort study*—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up  *Case-control study*—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls  *Cross-sectional study*—Give the eligibility criteria, and the sources and methods of selection of participants | Methods pages 4-7 |
| (*b*)*Cohort study*—For matched studies, give matching criteria and number of exposed and unexposed  *Case-control study*—For matched studies, give matching criteria and the number of controls per case | N/A |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | Methods page 4-7 |
| Data sources/ measurement | 8\* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | Methods page 4-7 |
| Bias | 9 | Describe any efforts to address potential sources of bias | Discussion pages 11-12 |
| Study size | 10 | Explain how the study size was arrived at | N/A: national data |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | Methods page 6-7 |
| Statistical methods | 12 | (*a*) Describe all statistical methods, including those used to control for confounding | Methods page 6-7 |
| (*b*) Describe any methods used to examine subgroups and interactions | Methods page 6-7 |
| (*c*) Explain how missing data were addressed | Methods page 6 |
| (*d*) *Cohort study*—If applicable, explain how loss to follow-up was addressed  *Case-control study*—If applicable, explain how matching of cases and controls was addressed  *Cross-sectional study*—If applicable, describe analytical methods taking account of sampling strategy | N/A |
| (*e*) Describe any sensitivity analyses | N/A |

|  |  |  |  |
| --- | --- | --- | --- |
| Results | | | |
| Participants | 13\* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | Methods pages 4-7 |
| (b) Give reasons for non-participation at each stage | N/A |
| (c) Consider use of a flow diagram | N/A |
| Descriptive data | 14\* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders | Results page 8-10, Table 1 pages 19-20 |
| (b) Indicate number of participants with missing data for each variable of interest | Valid N given in Results (pages 8-10) and Tables |
| (c) *Cohort study*—Summarise follow-up time (eg, average and total amount) | N/A |
| Outcome data | 15\* | *Cohort study*—Report numbers of outcome events or summary measures over time |  |
| *Case-control study—*Report numbers in each exposure category, or summary measures of exposure |  |
| *Cross-sectional study—*Report numbers of outcome events or summary measures | N given in Results (pages 8-10) and Tables |
| Main results | 16 | (*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included | Results pages 8-10, Tables 1-2, Supplementary Table |
| (*b*) Report category boundaries when continuous variables were categorized | N/A |
| (*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | N/A |
| Other analyses | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses | Results pages 8-10, Tables 1-2, supplementary table and figure, figs. 1-2 |
| Discussion | | | |
| Key results | 18 | Summarise key results with reference to study objectives | Discussion page 11 |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | Discussion pages 11-12 |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | Discussion page 12-13 |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results | Discussion pages 11-13 |
| Other information | | | |
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | Page 13 |

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.